Showing results (51-60 of 109) with videos related to

Sort By:
Pageof 11
Journal of Oncology|May 22, 2019
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?Giuseppe Bronte, Andrea Rocca, Sara Ravaioli, et al.
Cancers|March 10, 2022
The Role of <i>TP53</i> Mutations in <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for TherapyMatteo Canale, Kalliopi Andrikou, Ilaria Priano, et al.
Annals of the New York Academy of Sciences|January 15, 2005
Sex steroids, carcinogenesis, and cancer progressionLuigi Castagnetta, Orazia M Granata, Letizia Cocciadiferro, et al.
Oncology|February 14, 2012
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patientsDaniele Santini, Vladimir Virzi, Enrico Vasile, et al.
Oncotarget|February 27, 2016
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysisFrancesco Passiglia, Giuseppe Bronte, Viviana Bazan, et al.
Expert Opinion on Biological Therapy|February 28, 2013
Monoclonal antibodies in gastrointestinal cancersGiuseppe Bronte, Giuseppe Cicero, Stefania Cusenza, et al.
Cancer Reports (Hoboken, N.J.)|May 10, 2025
The Association Between Hepatocellular Carcinoma and Gastrointestinal Adenocarcinoma: Is This a New Syndrome in Patients With Cirrhosis? A Case SeriesFabrizio Bronte, Fabio D'Amato, Maria Rosa Barcellona, et al.
Cancer Treatment Reviews|December 7, 2010
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?Sergio Rizzo, Giuseppe Bronte, Daniele Fanale, et al.
Expert Opinion on Biological Therapy|September 12, 2015
Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Francesco Passiglia, Giuseppe Bronte, Marta Castiglia, et al.
Cancer Treatment Reviews|December 7, 2010
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinomaGiuseppe Bronte, Sergio Rizzo, Laura La Paglia, et al.
Pageof 11